z-logo
open-access-imgOpen Access
Clinicians’ Feedback on Patient/Carer Experience After Switching of Growth Hormone Treatment in Pediatric Patients During COVID-19
Author(s) -
Joanne Blair,
Kelly Warth,
Yashasvi Suvarna,
Marco Cappa
Publication year - 2021
Publication title -
patient preference and adherence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.885
H-Index - 48
ISSN - 1177-889X
DOI - 10.2147/ppa.s325914
Subject(s) - medicine , covid-19 , growth hormone , intensive care medicine , hormone , bioinformatics , pediatrics , virology , disease , infectious disease (medical specialty) , biology , outbreak
This study investigated why some clinicians switched growth hormone (GH) brands in pediatric patients with GH-related disorders to Norditropin ® since the start of the COVID-19 pandemic, the clinicians' perceptions of the results, and whether observations from this period of disruption could inform clinical practice in the future.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here